This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 120/9/753    most recent CIRCULATIONAHA.109.853077v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Belin de Chantemèle, E. J. Articles by Stepp, D. W. PubMed PubMed Citation Articles by Belin de Chantemèle, E. J. Articles by Stepp, D. W. Related Collections Obesity Peripheral vascular disease Other Vascular biology Related Articles

(Circulation. 2009;120:753-763.)
© 2009 American Heart Association, Inc.

Molecular Cardiology

Protein Tyrosine Phosphatase 1B, a Major Regulator of Leptin-Mediated Control of Cardiovascular Function

Eric J. Belin de Chantemèle, PhD; Kenjiro Muta, BS; James Mintz, BS; Michel L. Tremblay, PhD; Mario B. Marrero, PhD; David J. Fulton, PhD; David W. Stepp, PhD

From the Vascular Biology Center (E.J.B.d.C., K.M., J.M., M.B.M., D.J.F., D.W.S.) and Department of Physiology (D.W.S.), Medical College of Georgia, Augusta, Ga; and Goodman Cancer Center and Department of Biochemistry (M.L.T.), McGill University, Montreal, Quebec, Canada.

Correspondence to David W. Stepp, PhD, Vascular Biology Center, Medical College of Georgia, 1459 Laney Walker Blvd, Augusta, GA 30912. E-mail dstepp{at}mcg.edu

Received January 21, 2009; accepted June 22, 2009.

Background— Obesity causes hypertension and sympathoactivation, a process proposed to be mediated by leptin. Protein tyrosine phosphatase 1B (PTP1B), a major new pharmaceutical target in the treatment of obesity and type II diabetes mellitus, constrains the metabolic actions of leptin, but the extent to which PTP1B regulates its cardiovascular effects is unclear. This study examined the hypothesis that PTP1B is a negative regulator of the cardiovascular effects of leptin.

Methods and Results— PTP1B knockout mice had lower body fat but higher mean arterial pressure (116±5 versus 105±5 mm Hg, P<0.05) than controls. Leptin infusion produced a greater anorexic effect in PTP1B knockout mice and a marked increase in mean arterial pressure (135±5 mm Hg) in PTP1B knockout mice only. The decrease in mean arterial pressure in response to ganglionic blockade was higher in PTP1B knockout mice (–38±3% versus –29±3%, P<0.05), which suggests increased sympathetic tone. PTP1B deletion blunted mean arterial pressure responses to phenylephrine injection (55±10% versus 93±7%, P<0.05). Phenylephrine-induced aortic contraction was reduced in PTP1B knockout mice (57.7±9% versus 96.3±12% of KCl, P<0.05), consistent with desensitization to chronically elevated sympathetic tone. Furthermore, PTP1B deletion significantly reduced gene expression of 3 ₁-adrenergic receptor subtypes, consistent with blunted constriction to phenylephrine.

Conclusions— These data indicate that PTP1B is a key regulator of the cardiovascular effects of leptin and that reduced vascular adrenergic reactivity provides a compensatory limit to the effects of leptin on mean arterial pressure.

---

 

CLINICAL PERSPECTIVE

Related Articles:

Clinical Summaries
Circulation 2009 120: 717. [Extract] [Full Text]

Cardiovascular Side Effects of Antiobesity Drugs: A Yellow Flag in the Race to Safe Pharmacotherapy for Obesity

Allyn L. Mark
Circulation 2009 120: 719-721. [Extract] [Full Text]

This article has been cited by other articles:

				A. L. Mark Cardiovascular Side Effects of Antiobesity Drugs: A Yellow Flag in the Race to Safe Pharmacotherapy for Obesity Circulation, September 1, 2009; 120(9): 719 - 721. [Full Text] [PDF]